The debt-laden Chinese conglomerate Fosun controlled by billionaire entrepreneur Guo Guangchang has been looking to sell non-core assets, t...

A sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...

Gland Pharma reported revenues of Rs 3463 and a net profit of Rs 997 crore in FY21. Shares of Gland Pharma rose 1.89% to close at Rs 3360 o...

The blue-chip CSI300 index fell 0.1 per cent to 4,992.42, but the Shanghai Composite Index rose 0.3 per cent to 3,427.99 points.

The first phase of the China-based manufacturing facility will have production capacity of 200 million doses, Caixin said, citing people fa...

Fosun said it will be entitled to 60% of annual gross profit from sales of doses that it will make from imported bulk ingredients, and 65% ...

The company may raise up to $800 million or Rs 6,000 crore, a source with the knowledge of the matter said.

The Fosun Group is amongst China’s largest privately-owned investment conglomerates with interests spanning across pharmaceuticals, real es...

Fosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.

Symbiotec has been an acquisition target for other drug makers and PE players after the Indore-based company was put up for sale.

There have been reports that the CCEA has rejected Chinese firm Shanghai Fosun Pharmaceutical’s proposed $1.3 billion takeover of Indian co...

Gland Pharma Limited is seeking approval for its initial acquisition of up to 86.08 per cent by Shanghai Fosun Pharmaceutical (Group) Compa...

The deal would be the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd an...

Shanghai Fosun will acquire the shares held by Gland Pharma founders Ravi Penmetsa and his family and PE giant KKR.

Fosun has agreed to acquire 96 percent stake, which includes shares held by founders of Gland Pharma Ravi Penmetsa and family and private e...

Coming from behind in a closely fought race that saw US giant Baxter and private equity fund Advent make firm offers early May, Hong Kong-l...

The Hang Seng China Enterprises Index retreated for a seventh day, led by industrial and power companies.